Docetaxel, Cisplatin, Cetuximab and Bevacizumab Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab as Treatment for Patients with Locally Advanced Head and Neck Cancer
This is a Phase II study using a combination of chemotherapy and radiation therapy for treating head and neck cancer. The primary objective is to determine the rate of complete responses to treatment. The study will enroll 33 patients from the CTRC. In addition to other conditions for enrollment, eligible patients are those who have not been treated previously for head and neck cancer, have no evidence of metastatic disease, and who are otherwise in good health. Eligible patients have not been treated previously for head and neck cancer. Adult patients who have a history of active infection, active coronary artery disease, significant neurologic deficits, uncontrolled hypertension, heart attack or other cardiac complications, stroke, taking blood thinners or platelet lowering drugs, or an active ulcer may not be eligible to enroll.